most of our critical trial patients are critical and on ventilators too
READ: CytoDyn says Brazil approves pivotal Phase 3 clinical trial of leronlimab in critically ill coronavirus patients CytoDyn said the new pivotal Phase 3 clinical trial will focus on hospitalized critically ill COVID-19 patients who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation (ECMO). Its flagship Leronlimab drug will be administered via intravenous therapy (IV) in four doses or 700 milligrams (mg) per week. The trial is being conducted across 29 research centers with 316 patients.